BCM
ACHN

BlueCrest Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

BlueCrest Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,391
Closed -$53K – 1655
2018
Q3 		$53K Buy
+14,391
New +$42.9K ﹤0.01% 1435
2018
Q1 		– Sell
-72,566
Closed -$209K – 1703
2017
Q4 		$209K Buy
+72,566
New +$264K 0.01% 707

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlueCrest Capital Management's ACHN Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 14,391 shares — an estimated $53K sold.

BlueCrest Capital Management first reported a position in ACHN in Q4 2017 and held it in 2 quarters. The position peaked at $209K in Q4 2017. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 14,391 Achillion Pharmaceuticals shares in Q4 2018, an estimated $53K.
  • BlueCrest Capital Management first reported a position in Achillion Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's Achillion Pharmaceuticals position peaked at $209K in Q4 2017.
  • 121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.